Optomed PlcStock Exchange Release10 May 2022 at 14:00, Helsinki
Decisions of the Annual General Meeting and Board of Directors
Decisions of the Annual General Meeting:
The Annual General Meeting held on 10 May 2022 adopted the financial statements
for the financial period ended on 31 December 2021 and the remuneration report
for governing bodies and discharged the members of the Board of Directors and
the CEO from liability for the financial period ended on 31 December 2021.
The Annual General Meeting resolved in accordance with the proposal of the Board
of Directors that no dividend will be paid for the year 2021.
The number of members of the Board of Directors was confirmed as five. Xisi Guo,
Seppo Mäkinen, Petri Salonen, Reijo Tauriainen and Anna Tenstam were re-elected
as members of the Board.
The Annual General Meeting confirmed the annual Board remuneration as follows:
· Chairman of the Board EUR 36,000
· members of the Board EUR 18,000.
In addition, a meeting fee in the amount of EUR 300 is paid to the Chairpersons
and EUR 200 to members of the Committees for each Committee meeting. 40 percent
of the Board remuneration is paid in Optomed shares and 60 percent in cash. The
remuneration will be paid once a year in August, after Optomed’s H1 report has
been announced.
The Annual General Meeting decided to elect KPMG Oy Ab, a firm of authorized
public accountants, as the Company’s auditor. KPMG Oy Ab has informed the
Company that Authorized Public Accountant Tapio Raappana will continue as the
auditor with principal responsibility. Auditor’s remuneration will be paid in
accordance with an invoice approved by the Company.
The Annual General Meeting resolved in accordance with the Board’s proposal to
amend Section II.2.3 of Stock Option Plan 2017B to extend the subscription
period for shares by two (2) years, so that the subscription period pursuant to
all option rights granted under Stock Option Plan 2017B will end on 1 July 2024.
The General Meeting approved the authorization for the Board of Directors to
repurchase Optomed’s own shares and to accept them as pledge. Altogether no more
than 1,400,314 shares may be repurchased or accepted as pledge. The
authorization will be valid until the earlier of the end of the next Annual
General Meeting or 18 months from the resolution of the Annual General Meeting.
The General Meeting authorized the Board of Directors to decide on the issuance
of shares as well as the issuance of option rights and other special rights
entitling to shares referred to in Chapter 10, Section 1 of the Finnish
Companies Act. The number of shares to be issued based on this authorization may
not exceed 1,400,314. The Board of Directors is authorized to resolve on all
terms and conditions of the issuance of shares and special rights entitling to
shares, including the right to derogate from the pre-emptive right of the
shareholders. The authorization will be valid until the earlier of the end of
the next Annual General Meeting or 18 months from the resolution of the Annual
General Meeting.
Decisions of the Board of Directors:
At its meeting held after the Annual General Meeting, the Board of Directors
elected from among its members Petri Salonen as its Chairman. The committee
members were elected as follows:
Audit Committee:
· Reijo Tauriainen (Chairman)
· Seppo Mäkinen
· Anna Tenstam
Remuneration Committee:
· Seppo Mäkinen (Chairman)
· Reijo Tauriainen
· Anna Tenstam
Optomed Plc
Further enquiries
Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com
Optomed in Brief
Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld screening devices with
software and artificial intelligence with the aim to transform the diagnostic
process of blinding eye-diseases such as rapidly increasing diabetic
retinopathy. In its business Optomed focuses on eye-screening devices and
software solutions related R&D in Finland and sales through different channels
in over 60 countries.